• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral iron chelation is here.

作者信息

Kontoghiorghes G J

出版信息

BMJ. 1991 Nov 23;303(6813):1279-80. doi: 10.1136/bmj.303.6813.1279.

DOI:10.1136/bmj.303.6813.1279
PMID:1747667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1671411/
Abstract
摘要

相似文献

1
Oral iron chelation is here.口服铁螯合疗法出现了。
BMJ. 1991 Nov 23;303(6813):1279-80. doi: 10.1136/bmj.303.6813.1279.
2
Iron chelation.
J Assoc Physicians India. 1991 Sep;39(9):665-6.
3
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).去铁酮和去铁胺联合治疗对一名重症青少年血色素沉着症（JH）患者心脏并发症的逆转作用
Blood. 2007 Jan 1;109(1):362-4. doi: 10.1182/blood-2006-04-016949. Epub 2006 Sep 7.
4
Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).口服铁螯合作用：一篇特别强调印度关于去铁酮（L1）研究工作的综述。
Indian J Pediatr. 1993 Jul-Aug;60(4):509-16. doi: 10.1007/BF02751427.
5
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Minn Med. 2015 Jul;98(7):47.
6
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1712-3; author reply 1713-4.
7
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1712; author reply 1713-4.
8
Future of oral iron chelator deferiprone. (L1) ICOC committee.口服铁螯合剂去铁酮的未来。（L1）国际铁过载并发症委员会。
Lancet. 1993 Jun 5;341(8858):1479-80. doi: 10.1016/0140-6736(93)90925-7.
9
Iron chelation with oral deferiprone in patients with thalassemia.
N Engl J Med. 1998 Dec 3;339(23):1710-1; author reply 1713-4.
10
Iron-chelation therapy with oral deferiprone in patients with thalassemia major.口服去铁酮对重型地中海贫血患者进行铁螯合治疗。
N Engl J Med. 1995 Apr 6;332(14):918-22. doi: 10.1056/NEJM199504063321404.

引用本文的文献

1
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.地拉罗司和铁-麦芽酚：从发现到药物设计、研发、临床应用及未来前景的四十年。
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
2
New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.使用三价麦芽酚铁和其他亲脂性铁螯合剂复合物治疗缺铁性贫血的新时代：发现的历史视角和未来应用。
Int J Mol Sci. 2021 May 24;22(11):5546. doi: 10.3390/ijms22115546.
3

本文引用的文献

1
The law and Lewis Carroll.
Semin Nephrol. 1986 Mar;6(1):1-2.
2
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.口服螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮对β地中海贫血中铁的有效螯合作用
Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12. doi: 10.1136/bmj.295.6612.1509.
3
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮在人体中的药代动力学研究。
The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.
去铁酮（L1）的历史及地中海贫血铁过载完全治疗的范例
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020011. doi: 10.4084/MJHID.2020.011. eCollection 2020.
4
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.地中海贫血和弗里德赖希共济失调从致命疾病向慢性病的转变。
World J Methodol. 2014 Dec 26;4(4):197-218. doi: 10.5662/wjm.v4.i4.197.
5
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
6
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
7
Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.地中海贫血及其他疾病中口服铁螯合疗法的现状与未来前景
Indian J Pediatr. 1993 Jul-Aug;60(4):485-507. doi: 10.1007/BF02751425.
8
Oral iron chelation is here.口服铁螯合疗法问世了。
BMJ. 1991 Dec 14;303(6816):1545-6. doi: 10.1136/bmj.303.6816.1545-c.
Clin Pharmacol Ther. 1990 Sep;48(3):255-61. doi: 10.1038/clpt.1990.147.
4
Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia.口服螯合剂L1及其他α-酮羟基吡啶在治疗地中海贫血输血性铁过载中的设计、特性及有效应用
Ann N Y Acad Sci. 1990;612:339-50. doi: 10.1111/j.1749-6632.1990.tb24321.x.
5
L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
Br J Haematol. 1990 Dec;76(4):550-3. doi: 10.1111/j.1365-2141.1990.tb07915.x.
6
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）的长期试验。II. 临床观察。
Br J Haematol. 1990 Oct;76(2):301-4. doi: 10.1111/j.1365-2141.1990.tb07888.x.
7
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）的长期试验。I. 铁螯合与代谢研究。
Br J Haematol. 1990 Oct;76(2):295-300. doi: 10.1111/j.1365-2141.1990.tb07887.x.
8
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Lancet. 1990 Nov 24;336(8726):1275-9. doi: 10.1016/0140-6736(90)92962-h.
9
Oral iron chelation with L1.
Lancet. 1990 Mar 10;335(8689):601. doi: 10.1016/0140-6736(90)90380-n.